TRANSIENT AAV
PRODUCTION

Transient AAV Production

Our transient expression platform comprises optimised proprietary XAAV™ plasmids and a GMP-banked clonal suspension HEK293 cell line. We have reconfigured the Rep and Cap genes to place Cap under the control of a strong CMV promoter, while Rep is expressed at a lower level via an EMCV internal ribosome entry site. This results in a higher viral titre, better per cell rAAV productivity and improved full:empty vector ratio. We've also improved adenoviral helper functionality by simplifying the Ad5 helper plasmid, which doesn't contain any adenoviral hexon genes; an added benefit when it comes to regulatory approval.

We offer expert cloning and engineering services to customise and optimise our XAAV™ plasmids for expression of your gene of interest, before process development and manufacture of your rAAV vectors at any grade and scale.